Investor Presentaiton

Investor presentation Full year 2018 Slide 90 The obesity pipeline consists of projects addressing both appetite reduction and energy expenditure How to address obesity from a medical perspective Novo Nordisk obesity products and pipeline Weight reduction by reducing food intake increasing energy expenditure Weight reduction by Projects: SaxendaⓇ semaglutide - QW GLP-1 2019 expectations Launched Phase ongoing - PYY analogue NN9277-GG-co-agonist AM833 amylin analogue PYY1562 Phase 2 initiation Phase 1 results Phase 1 results NN9423 - Tri-agonist 1706 Phase 1 results PYY1875 - PYY analogue Phase 1 ongoing Appetite reduction changing diabetes Impact on metabolic changes to increase lipid and glucose metabolism Appetite reduction Energy expenditure Appetite reduction and energy expenditure QW: Once-weekly novo nordisk

View entire presentation